NCT06345898View on ClinicalTrials.gov

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

November 30, 2033

Study Completion Date

November 30, 2033

Conditions

X Linked Retinoschisis

Interventions

DRUG

JWK002

Subretinal administration of gene therapy vector JWK002 to one eye.

Trial Locations (1)

610023

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER